Mar 15, 2018 11:30 am UTC| Business
NEW YORK, March 15, 2018 -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel...
Mustang Bio Announces Key Leadership Appointments
Mar 15, 2018 11:30 am UTC| Business
NEW YORK, March 15, 2018 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor...
Study Demonstrates Potential for SMRT Sequencing to Improve the Safety of Gene Therapy Protocols
Mar 15, 2018 11:30 am UTC| Business
MENLO PARK, Calif., March 15, 2018 -- A new publication in the journal of the American Society of Gene Cell Therapy demonstrates the utility of Single Molecule, Real-Time (SMRT®) Sequencing to assess the quality of...
Titan Medical to Present at the 28th Annual Oppenheimer Healthcare Conference
Mar 15, 2018 11:30 am UTC| Business
TORONTO, March 15, 2018 -- Titan Medical Inc. (TSX:TMD) (OTCQB:TITXF) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally...
Albireo Reports Fourth Quarter and Year-End 2017 Financial Results
Mar 15, 2018 11:30 am UTC| Business
— Phase 3 PFIC trial of IBAT inhibitor A4250 planned to initiate in spring 2018 — — Elobixibat approved in Japan, becoming the first IBAT inhibitor approved in the world — — ~$200 million current cash balance expected...
Mar 15, 2018 11:30 am UTC| Business
NEW YORK, March 15, 2018 -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that preclinical data for TG-1601, the Company’s novel BET inhibitor, has been selected for presentation at the upcoming American...
Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update
Mar 15, 2018 11:30 am UTC| Business
- Responses observed in second solid tumor with NY-ESO providing further evidence of the potential of our SPEAR TCR T‑cell therapies to treat solid tumors - - Clinical momentum continues: dosing patients in MAGE-A4...